



The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

624.HODGKIN LYMPHOMAS AND T/NK CELL LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL

The Role of Radiotherapy in Patients with Refractory Hodgkin Lymphoma after Brentuximab Vedotin and -/or Immune Checkpoint Inhibitors

Ting-Bo Liu, MD¹, Xiaofan Li, MD PhD², Rui-Zhi Zhao³, Han Shao⁴, Gui-Qing Shi³, Yan-Yan Qiu³, Tian-Lan Tang³, Yu-Ping Lin³, Si-Lin Chen³, Cheng Huang³, Si-Qin Liao³, Jin-Hua Chen³, Hai-Ying Fu⁵, Jian-Zhi Liu³, Jian-Zhen Shen³, Ben-Hua Xu³, Yu-jing Zhang⁴, Yong Yang, MD³

¹ Fujian Medical University Union Hospital, Fuzhou, CHN

² Union Clinical Medical Colleges, Fujian Medical University, Fuzhou, China

³ Fujian Medical University Union Hospital, Fuzhou, China

⁴ Sun Yat-sen University Cancer Center, Guangzhou, China

⁵ The Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, China

Background: Brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs) had important roles in the treatment of relapse or refractory (R/R) Hodgkin lymphoma (HL). Treatment of refractory disease after BV and -/or ICIs remains a challenge. This study was conducted to evaluate the efficacy and safety of radiotherapy for R/R HL after failure to BV or ICIs.

Patients and methods: We retrospectively analyzed patients in two institutions with R/R HL who had failed after first-line therapy, and were refractory to BV or ICIs, and received radiotherapy (RT) thereafter. The overall response rate (ORR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were analyzed.

Results: A total of 19 patients were enrolled. First-line systemic therapy consisted of ABVD (84.2%), AVD + ICIs (10.5%) and BEACOPP (5.3%), respectively. After first-line therapy, 15 patients (78.9%) were refractory, and 4 patients (21.1%) relapsed. After diagnosis of R/R HL, 8 patients (42.1%) received BV, and 17 patients (89.5%) received ICIs. RT was delivered in all 19 patients who failed after BV or ICIs. In 16 efficacy-evaluable patients, the ORR and CR rate were 100% and 100%. The median DOR was 17.2 months (range, 7.9 to 46.7 months). 3 patients progressed at outside of the radiation field. The in-field-response rate was 100%. The 12-month PFS and OS were 84.4% and 100%, respectively. No patients were reported with sever adverse events.

Conclusion: This study concluded that radiotherapy was effective and safe for refractory HL after BV or ICIs. Further prospective studies were warranted.

KEY WORDS: Radiotherapy; Hodgkin lymphoma; Brentuximab vedotin; Immune checkpoint inhibitors; Refractory; Relapse

Disclosures No relevant conflicts of interest to declare.

<https://doi.org/10.1182/blood-2023-184773>